

DVD 1: Plenary Session I

Molecular Abnormalities and Gene Expression Changes in AML. Are we Ready for a Prognostic Molecular Prioritization? What is the impact on Personalized AML Therapy?

Torsten Haferlach, MD

CLL: How Much Progress? What is the Future?

Michael J. Keating, MB, BS

Close to the Cure in CML

Moshe Talpaz, MD

DVD 2: Chronic Lymphocytic Leukemia, Part I

FCR Now Frontline Therapy

Michael Hallek, MD

Do the Biologic Factors add any Significance over the Clinical and Classical Prognostic Factors?

William Wierda, MD, PhD

Role of Old and New Monoclonal Antibodies, Alone and in Combinations

Jeffrey A. Jones, MD

Novel Inhibitors of B-Cell Signaling

Susan O'Brien, MD

Transplant in CLL--When, How, and What to Expect

Issa Khouri, MD

What do the Genetics Tell us? Can we Translate the Findings into Therapies?

Carlo M. Croce, MD

Treatment in CLL - the Age Old Question

Peter Hillmen, MD, PhD

DVD 3: Chronic Lymphocytic Leukemia, Part II

Debate: Fludarabine vs. Chlorambucil. Is the Battle Over?

Chlorambucil – Still Not Bad

Daniel Catovsky, MD, DSc, FMedSci

Fludarabine the Winner

Kanti Rai, MD

IMiDs Combinations in CLL

Alessandra Ferrajoli, MD

How Can We Exploit the CLL Microenvironment?

Jan A. Burger, MD, PhD

DVD 4: Acute Lymphoblastic Leukemia

Treatment of Adolescents and Young Adults – Pediatric versus Adult Regimens?

Ching-Hon Pui, MD

Monoclonal Antibodies in ALL Therapy – Any Progress?

Deborah Thomas, MD

Targeted Therapies in Ph-positive ALL: Which is the Best TKI? What is the Role of Chemotherapy?

Farhad Ravandi, MD

Minimal Residual Disease: What Does it Mean? Is it now a Therapeutic Target?

Wendy Stock, MD

Novel Drugs and Strategies in ALL: Breakthroughs on the Horizon?

Susan O'Brien, MD

Allogeneic SCT for ALL in CR1: Grounds for Optimism?

Anthony H. Goldstone, FRCR(M)

DVD 5: Myeloproliferative Disorders

Pathophysiology of MPDs and Role of JAK2 Mutations

Ross L. Levine, MD

JAK2 Inhibitors – Are they the Solution?

Srdan Verstovsek, MD, PhD

Role of IMiDs in Myelofibrosis

Animesh Pardanani, MD

Interferon Alfa in PV and ET

Jean-Jacques Kiladjian, MD, PhD

Prognostic Factors and Models in PV, ET, and MF

Francesco Passamonti, MD

DVD 6: Myelodysplastic Syndromes Part I, Plenary Session II

Progress with Epigenetic Therapy in MDS – Are We Stuck?

Pierre Fenaux, MD, PhD

Plenary Session II

Cure of Myeloma, A Personal Odyssey

Bart Barlogie, MD

Any Progress in MPDs?

Ayalew Tefferi, MD

Debate: Iron Chelation Therapy in MDS – Is it Useful?

Absolutely Necessary to Improve Outcome

Luca Malcovati, MD

No Data to Prove its Benefit

Ayalew Tefferi, MD

DVD 7: Myelodysplastic Syndromes Part II

SNPs and other Molecular Changes in MDS – Ready for Primetime?

Jaroslav P. Maciejewski, MD, PhD, FACP

Novel Pathophysiologic Pathways in MDS

Benjamin Ebert, MD, PhD

IMiDs in MDS -- What Have We Learned So Far?

Mikkael A. Sekeres, MD, MS

Prognostic Factors and Risk Models in MDS

David P. Steensma, MD, FACP

Debate: Role of Allogeneic SCT in MDS

Critical to Cure MDS

Theo de Witte, MD, PhD

Minimal Benefit in MDS

Guillermo Garcia-Manero, MD

Novel Agents and Strategies in MDS

Stefan Faderl, MD

Growth Factors (EPO, G-CSF, TPO) in the Modern Era

Eva S. Hellström-Lindberg, MD, PhD

DVD 8: Acute Myeloid Leukemia Part I

State of the Art Therapy of Younger AML – Lesson from Large Randomized Clinical Trials

Stefan Faderl, MD

Debate: Treatment of Older AML

Intensive Chemotherapy is the Best Approach

Gunnar Juliusson, MD

Low Intensity Therapy is the Way of the Future

Alan K. Burnett, MD

DVD 8: Acute Myeloid Leukemia Part I
(...cont)

State of the Art Therapy of APL – The Lo Coco Approach

Francesco Lo Coco, MD

Role of Allogeneic SCT in CR1

Frederick R. Appelbaum, MD

FLT3 Mutations and FLT3 Inhibitors – Last Nail in Coffin or Resuscitation

Mark Levis, MD, PhD

New Treatments and Strategies in AML

Farhad Ravandi, MD

DVD 9: Acute Myeloid Leukemia Part II

Marrow Microenvironment and Targeted Therapies

Marina Konopleva, MD, PhD

Micro RNA and Molecular Profiling in AML – Is it Relevant?

Guido Marcucci, MD

WBC Transfusions, Irradiated, Unirradiated?

Gloria N. Mattiuzzi, MD

DVD 10: Multiple Myeloma

Pathophysiology of Myeloma – Lessons into the Clinic

Kenneth C. Anderson, MD

SCT Improves Outcome in Myeloma

Bart Barlogie, MD

Novel Agents and Combinations in Myeloma

Antonio Palumbo, MD

DVD 10: Multiple Myeloma (...cont)

Adverse Cytogenetic and Biologic Factors in Myeloma

Sagar Lonial, MD

IMiDs, Proteasome Inhibitors, Combos. What is Best?

Robert Z. Orlowski, MD, PhD

Waldenstrom's Macroglobulinemia – Where does Therapy Stand?

Irene M. Ghobrial, MD

DVD 11: Lymphoma

Any Progress Since R-CHOP?

John Sweetenham, MD

Is Bendamustine + Rituxan the Best Treatment for Indolent Lymphoma?

Mathias J. Rummel, MD, PhD

What is Optimal Therapy in Early Large Cell Lymphoma?

Fredrick B. Hagemeister, MD

Indolent Lymphomas – Observe, BR, RCHOP, Others?

Peter McLaughlin, MD

Hodgkin's Disease – Cured but not Conquered

Anas Younes, MD

DVD 12: Chronic Myeloid Leukemia

Debate: What is the Ideal Frontline CML Therapy?

Imatinib

Jane F. Apperley, MD

2nd Generation TKIs

Giuseppe Saglio, MD

Salvage Strategies Post Imatinib Failure – What to do Now?

Jorge E. Cortés, MD

Debate: Optimal Monitoring in CML?

Intensive Monitoring is Essential

Tim Hughes, MD, MBBS

Too Much for Too Little

Charles A. Schiffer, MD

Debate: Role of Allogeneic SCT

As Salvage Post Imatinib Failure

Richard Champlin, MD

As Salvage Post 2 TKI Failures

Elias Jabbour, MD

Do We Have Better Prognostic Tools in CML?

Michael Deininger, MD, PhD

Can We Improve on Frontline CML Therapy?

David Marin, MD

DVD 13: Special Topics

State of the Art New Antifungals

Dimitrios Kontoyiannis, MD

Allogeneic SCT in Leukemias – Overview

Sergio Giralt, MD

Multipotent Mesenchymal Stromal Cells (MSC) – Evolving Role in Cancer and Leukemia Therapy

Michael Andreeff, MD, PhD

Interesting Statistics in Leukemia

Elihu H. Estey, MD